Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188561 | 1.00 | PDE5A (0.38) | PDE5AMAPTHSD11B1CYP2C9MRGPRX4 | |
| SCHEMBL601842 | 1.00 | PDE5A (0.38) | PDE5AMAPTHSD11B1CYP2C9MRGPRX4 | |
| SCHEMBL601843 | 1.00 | PDE5A (0.38) | PDE5AMAPTHSD11B1CYP2C9MRGPRX4 | |
| SCHEMBL14973519 | 0.89 | CYP2C9 (0.49) | MAPTCYP2C9LMNAALDH1A1GPR119 | |
| SCHEMBL14973522 | 0.89 | CYP2C9 (0.49) | MAPTCYP2C9LMNAALDH1A1GPR119 | |
| SCHEMBL10188562 | 0.85 | ALDH1A1 (0.42) | MAPTCYP2C9LMNAALDH1A1 | |
| SCHEMBL601429 | 0.85 | ALDH1A1 (0.42) | MAPTCYP2C9LMNAALDH1A1 | |
| SCHEMBL10188595 | 0.81 | NPC1 (0.42) | PDE5AMAPTCYP2C9MRGPRX4LMNA | |
| SCHEMBL600832 | 0.81 | NPC1 (0.42) | PDE5AMAPTCYP2C9MRGPRX4LMNA | |
| SCHEMBL20524971 | 0.77 | MAPK1 (0.45) | PDE5AMAPTCYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| CN-102365273-A | Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof | SANOFI AVENTIS | 2012-02-29 | — | — | CN | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | PDE5A 444/4885MAPT 2666/4885HSD11B1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.